Home / People / Stefan Lüft
Portrait ofStefan Lüft

Stefan Lüft

Partner
Rechtsanwalt

CMS Hasche Sigle
Nymphenburger Straße 12
80335 Munich
Germany
Languages German, English

Stefan Lüft is an intellectual property expert, advising German and international companies on patents, copyright, trademarks, design, know-how protection and unfair competition, including licensing agreements as well as research and development cooperations. In the life sciences sector, Stefan’s practice also covers regulatory questions. His clients include manufacturers of electrical household appliances and consumer electronics, pharmaceutical companies, automotive suppliers as well as IT, media and telecommunication companies. He also represents companies before court and in arbitration proceedings.

Stefan joined CMS in 1992 and became a partner in 1999. He lectures in patent law at the Brandenburg University of Technology Cottbus-Senftenberg and co-authored a commentary on copyright law.

more less

„Oft empfohlen“ für Marken- und Wettbewerbsrecht

JUVE Handbuch, 2023/2024

„kompetenter u. kollegialer Wettbewerbsrechtler“, Wettbewerber

JUVE Handbuch, 2023/2024

Relevant experience

  • Advising an automotive supplier on patent infringement lawsuits
  • Advising a manufacturer of medical devices on patent infringement lawsuits
  • Advising an online retailer on competition law disputes
  • Advising a manufacturer of household appliances on competition law disputes
  • Advising a biotech company on option and cooperation contracts with an international pharmaceutical company
more less

Memberships & Roles

  • German Association for the Protection of Intellectual Property (GRUR)
more less

Education

  • 1990 - 1992: Trainee lawyer with Higher Regional Court Munich
  • 1985 - 1990: Law studies in Munich
more less

Feed

26/03/2024
CMS advises sellers of Cardior Pharmaceuticals on potential acquisition...
Munich – CMS advises the sellers of Cardior Pharmaceuticals in the potential acquisition of the company by Novo Nordisk. Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions. It is expected to happen in the second quarter of 2024.A CMS team headed by Lead Partners Stefan-Ulrich Müller, Dr Tilman Weichert and Jörg Schrade advised the sellers of Cardior Pharmaceuticals on all legal aspects of the transaction. Cardior Pharmaceuticals GmbH, based in Hannover, Germany, is a leading clinical-stage bio­phar­ma­ceut­ic­al company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. CMS Germany Stefan-Ulrich Müller, Lead Partner Dr Tilman Weichert, Lead Partner Dr Michael Wangemann, Partner Dr Kai Wallisch, Partner Dr Thomas Mühl, Principal Coun­sel Se­basti­an Hummel, Senior As­so­ci­ate Vikt­or­ia Barthel, Senior As­so­ci­ate Mar­i­elouise Emmer, Senior Associate Dr Carl-Friedrich Thoma, Senior Associate Dr Stefan Kühl, Senior Associate Dr Alexander Weinhold, Senior Associate Maria Kucher, Associate Jonas Ohmann, Associate Dr Josephine Doll, Associate Dr Christian Seeburger, Associate Sonja Schanze, Associate, all Corporate/M&A Dr Marie-Luisa Loheide, Associate, Private Clients Jörg Schrade, Lead Partner Eduard Kosavtsev, Senior Associate, both Tax Stefan Lehr, Partner, Antitrust, Competition & Trade Stefan Lüft, Partner, IP Dr Benedikt Forschner, Partner, Labor, Employment & Pensions Dr Markus Kaulartz, Partner Dr Fiona Savary, Counsel Dr Felix Glocker, Senior Associate, all TMC Dr Tilman Niedermaier, Partner Susanne Schwalb, Partner, both Dispute ResolutionPress Con­tact presse@cms-hs. com
20/03/2024
CMS advises listed company Mutares on agreement to acquire Magirus from...
Munich – Listed private equity firm Mutares SE & Co. KGaA has signed an agreement to acquire Magirus from the Iveco Group. Magirus is one of the world’s leading providers of firefighting equipment. This new platform investment will enable Mutares to strengthen its Goods & Services segment. The transaction is expected to complete no later than January 2025.A CMS team headed by partner Dr Michael Wangemann advised Mutares on all legal aspects of the acquisition. Mutares regularly relies on the expertise of the CMS team led by Dr Wangemann, including during the recent acquisition of High Precision Components Witten GmbH. Mutares SE & Co. KGaA is a private equity firm based in Munich. It acquires medium-sized companies in transitional situations and parts of large corporations (carve-outs), with the aim of putting them onto a profitable growth path. Mutares’ revenues currently stand at around EUR 5 billion and are expect to rise to 10 billion by 2028. Ulm-based Magirus generates annual sales of more than EUR 300 million. The company has around 1,300 employees across locations in Germany, Italy, Austria and France. It offers products and related aftersales services in the firefighting and disaster control field. CMS Germany Dr Michael Wangemann, Lead Partner Viktoria Barthel, Senior As­so­ci­ate Mar­i­elouise Emmer, Senior Associate, all Corporate/M&A Anna-Lena Löcherbach, Counsel, M&A/Real Estate Susanne Schwalb, Partner, Dispute Res­ol­u­tion Stefan Lüft, Partner Martin Maurer, Senior Associate, both IP Inhouse Legal at Mutares Jan Thöle, General Counsel Inhouse Tax at Mutares Denis Ahluwalia, Head of Tax Julia Hellwig, Senior Manager TaxPress Con­tact presse@cms-hs. com
18/03/2024
CMS advises biotechnology firm Tubulis on EUR 128 million Series B2 financing...
Munich – Munich-based biotech company Tubulis has announced the successful completion of its extended and over-subscribed Series B2 round of financing, which raised EUR 128 million. This latest round was led by EQT Life Sciences and Swiss biotech investor Nextech Invest Ltd., representing funds that it manages. Other investors included US funds Frazier Life Sciences and Deep Track Capital along with all the existing investors, including Andera Partners, BioMedPartners, Fund+, Bayern Kapital’s ScaleUp-Fonds Bayern, Evotec, coparion, Seventure Partners, Occident and High-Tech Gründerfonds (HTGF). Tubulis will use the capital raised to develop the firm’s pipeline of next-generation antibody-drug conjugates (ADCs). The aim is also to complete the first clinical evaluation of its two drug candidates and to drive forward the company’s planned US expansion.A CMS team headed by partner Stefan-Ulrich Müller advised Tubulis on all legal aspects of the Series B2 financing. The team led by Stefan-Ulrich Müller has been advising Tubulis for several years now, including on the preceding EUR 60 million Series B round of financing. This work is another excellent example of the wide-ranging advisory services that CMS offers in the Lifesciences & Healthcare sector. CMS Germany Stefan-Ulrich Müller, Lead Part­ner Se­basti­an Hummel, Senior Associate Maria Kucher, Associate, all Corporate/M&A, Venture Capital Stefan Lüft, Partner, Intellectual Property Jörg Schrade, Partner, Tax Stefan Lehr, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com
01/02/2024
Early days of the UPC - key issues and take-aways
 
30/11/2023
CMS advises Rügenwalder Mühle shareholder on investment by Pfeifer & Langen
Munich – Family-owned firm Pfeifer & Langen has taken a majority stake in Rügenwalder Mühle, a branded manufacturer that is considered a pioneer in vegetarian/vegan alternatives to meat and sausages...
10/11/2023
CMS advises clean tech start-up DACMA on investment by Repsol
Munich – The clean-tech start-up DACMA GmbH has secured further funding to accelerate Direct Air Capture (DAC) through an investment by Repsol Energy Venture S.A. With this partnership, Repsol and DACMA...
27/09/2023
Successful with CMS at Dusseldorf Higher Regional Court:
Dusseldorf – The Chinese medical device manufacturer Shenzhen Mindray Medical Instruments has been successful with a preliminary injunction against its competitor Shenzhen Comen Medical Instruments...
12/07/2023
International CMS team advises shareholders of cleaning systems manufacturer...
Munich – Freudenberg Home and Cleaning GmbH, an international supplier of branded cleaning products and systems as well as laundry care products, has acquired VERMOP Salmon GmbH, a German manufacturer...
11/05/2023
CMS advises Tengelmann Ventures portfolio company Pomélo + Co on the acquisition...
Munich – Pomélo + Co GmbH, which specialises in beauty and personal care, has acquired all the assets of Shyne Labs AG and its range of brands. Through the acquisition, Pomélo + Co is further expanding...
05/04/2023
CMS advises 7-Industries on Series C financing round for space start-up...
Munich – Space start-up Isar Aerospace, developer and manufacturer of launch vehicles for transporting small and medium-sized satellites, has completed a Series C financing round of around EUR 155 million...
29/03/2023
Webinar: Getting to grips with changes to consumer regulation
At a time when competition for customer spend is high, don’t fall foul of changes to consumer protection law. The risks of non-compliance are substantial - reputational damage, civil and criminal penalties and loss of business. Join our webinar on Wednesday 29 March to understand the requirements of the Digital Services Act, dark patterns and the new price reduction obligations under the Price Indication Directive. We will also discuss specific consumer law developments in the UK, Germany and Spain. The webinar will be moderated by Katie Nagy de Nagybaczon, Part­ner & Co-Head of Consumer Products Sector Group and will include the following experts:Melanie Shefford - Of Counsel, Technology, Media and Com­mu­nic­a­tions Alf­onso Codes - Partner, Public Law & Regulated SectorsJuan Moreno - Counsel, Public Law & Regulated SectorsStefan Lüft - Partner, Intellectual Property
24/02/2023
CMS advises shareholders of Factor Eleven on their Exit to Armira
Munich – Factor Eleven, a leading digital marketing software company, announces a strategic collaboration with Armira, an investment holding company focused on family businesses and tech­no­logy. The...